TSW
TEVA icon

Thompson Siegel & Walmsley’s Teva Pharmaceuticals TEVA Stock Holding History

Thompson Siegel & Walmsley’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-1,606,255
Closed -$28.3M – 879
2017
Q3 		$28.3M Sell
1,606,255
-816,227
-34% -$18.4M 0.34% 86
2017
Q2 		$80.5M Buy
2,422,482
+49,885
+2% +$1.54M 0.95% 35
2017
Q1 		$76.1M Sell
2,372,597
-1,888,255
-44% -$64.4M 0.89% 29
2016
Q4 		$154M Buy
4,260,852
+984,040
+30% +$39.3M 2.03% 1
2016
Q3 		$151M Buy
3,276,812
+762,044
+30% +$39.8M 2.34% 1
2016
Q2 		$126M Buy
2,514,768
+282,843
+13% +$15.1M 1.99% 1
2016
Q1 		$119M Buy
2,231,925
+361,070
+19% +$21.2M 1.94% 1
2015
Q4 		$123M Buy
1,870,855
+362,150
+24% +$22.4M 2.21% 1
2015
Q3 		$85.2M Buy
1,508,705
+350,040
+30% +$22.7M 1.59% 2
2015
Q2 		$68.5M Buy
1,158,665
+72,020
+7% +$4.44M 1.21% 5
2015
Q1 		$67.7M Buy
1,086,645
+1,086,450
+557,154% +$63.2M 1.17% 5
2014
Q4 		$11K Hold
195
– – ﹤0.01% 621
2014
Q3 		$10K Hold
195
– – ﹤0.01% 621
2014
Q2 		$10K Hold
195
– – ﹤0.01% 604
2014
Q1 		$10K Sell
195
-700
-78% -$32.4K ﹤0.01% 589
2013
Q4 		$36K Sell
895
-4,275
-83% -$168K ﹤0.01% 482
2013
Q3 		$195K Sell
5,170
-679,918
-99% -$26.5M ﹤0.01% 389
2013
Q2 		$26.9M Buy
+685,088
New +$26.7M 0.58% 45

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NC
Northern Cross Boston, Massachusetts $279M AUM 1.98% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

Thompson Siegel & Walmsley's TEVA Position: Q4 2017 in Review

Thompson Siegel & Walmsley sold out of Teva Pharmaceuticals (TEVA) in Q4 2017, closing a stake of 1,606,255 shares — an estimated $28.3M sold.

Thompson Siegel & Walmsley first reported a position in TEVA in Q2 2013 and held it in 18 quarters. The position peaked at $154M in Q4 2016. 508 funds tracked by Wall St. Rank hold TEVA as of Q4 2017.

  • Thompson Siegel & Walmsley reported no remaining Teva Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
  • Thompson Siegel & Walmsley sold 1,606,255 Teva Pharmaceuticals shares in Q4 2017, an estimated $28.3M.
  • Thompson Siegel & Walmsley first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 18 quarters.
  • Thompson Siegel & Walmsley's Teva Pharmaceuticals position peaked at $154M in Q4 2016.
  • 508 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2017.

Based on Thompson Siegel & Walmsley's 13F filing for Q4 2017, filed 9 Feb 2018.